On March 14, 2013, IHPC filed an Amicus Brief in support of Myriad Genetics in The Association for Molecular Pathology v. Myriad Genetics. The brief provides a comprehensive analysis on the values of patenting genes for biotech industry and argued that the validity of gene-based patents is critical for companies to secure necessary funding for research development, enhanced collaborations with academia and non-profit research organizations which all lead to disruptive innovations and solve unmet medical needs. Human Genome Sciences (acquired by GlaxoSmithKline in 2012) serves as a successful example establishing that gene patenting is important for sustainable growth for biotech companies.
Read more about the Brief: http://www.americanbar.org/content/dam/aba/publications/supreme_court_preview/briefs-v2/12-398_resp_amcu_ipc.authcheckdam.pdf
